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1. Introduction 
Transthyretin (TTR) amyloidosis is classified into systemic senile amyloidosis (SSA), due to 
senescent events caused by the wild type TTR gene, and familial amyloidotic 
cardiomyopathy (FAC) and familial amyloidotic polyneuropathy (FAP), which are inherited 
diseases caused by mutant TTR genes (Ando et al., 2005; Buxbaum, 2009; Rapezzi et al., 
2010). TTR is biochemically stable as a tetramer; however unstable as a monomer when the 
amyloid fibrillogenesis is higher (Damas et al., 2005). Non-fibrillar TTR deposits can be first 
detected immunohistochemically in the heart of humans with SSA, and finally in the 
peripheral nerves of those with FAP. After the non-fibrillar TTR deposits, congophilic 
and/or fibrillar amyloids consisting of TTR can be detected and are consistent with 
immunopositive lesions for TTR (Damas et al., 2005; Sousa et al., 2002). 
Although animal models of SSA and FAP are strong tools to develop therapeutic agents and 
diagnostic materials, as well as to understand the pathomechanism (Buxbaum, 2009), 
spontaneous TTR amyloidosis has not yet been reported in animals. Therefore, a model has 
been developed using transgenic (Tg) techniques, such as Tg mice and rats with human 
mutant TTR genes (Buxbaum, 2009; Ueda et al., 2007). However, these model rodents do not 
show enough phenotypes resembling the clinical signs and histopathological features of 
SSA and FAP. In histopathological examinations, some Tg rodents tended to be hardly 
detected with fibrillar amyloid deposits, even if they reveal abundant non-fibrillar TTR 
immunoreactivity. 
Nakamura et al. (2008) observed SSA in an aged vervet monkey that showed typical clinical 
symptoms and histopathological features, as well as the human form of SSA. Furthermore, 
another group followed up on our findings (Chambers et al., 2010). Both cases revealed not 
only non-fibrillar TTR immunoreactivity but also fibrillar amyloid deposits. Thus, since the 
vervet monkey shows more mature TTR amyloid formation than Tg rodents, it could be a 
novel animal model for TTR amyloidosis. 
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2. Animal models for TTR amyloidosis 
2.1 Rodent models  
The main strategy used to develop an animal model for TTR amyloidosis is to transfect mutant 
human TTR genes to mice because spontaneous TTR amyloidosis has not been reported in 
mammalian species before 2008 other than in humans. Because TTR is synthesized from 
hepatocytes, most Tg rodent lines are produced using the hepatocyte-specific metallothionein 
promoter (Karin et al., 1987). The first Tg mice, transfected with human V30M TTR (valine 
substituted for methionine at the human TTR 30 residue), expressed mutant TTR in the fetal 
liver and yolk sac (Yamamura et al., 1987) and showed significant increase in serum 
concentrations of a TTR variant (Sasaki et al., 1986) but failed to show TTR immunoreactivity 
or amyloid deposits. Yi et al. (1991) improved the next Tg mouse line, which they attempted to 
create by transfecting mice with an increased number of TTR V30M gene copies. This Tg line 
showed slight TTR amyloid deposition in the gastrointestinal and cardiovascular organs in 6-
month-old mice, which revealed SSA-like systemic amyloid deposits at 24 months. Takaoka et 
al. (1997) inserted 0.6 kb or 6 kb fragments upstream of the V30M TTR gene. Tg mice with the 
6-kb upstream insert showed a high enough concentration of human TTR in serum, 
corresponding with that in normal humans, but 10-fold greater than that in wild type-mice. An 
increasing TTR concentration was seen in 1-month-old animals with the 6-kb upstream insert, 
whereas TTR amyloid deposits appeared in the gastrointestinal tract of mice at 9 months and 
in their systemic organs at 21 months. In Tg mice with the 0.6-kb upstream insert, some 
amyloid deposits appeared at 15 months, particularly in the gastrointestinal tract. The density 
of the amyloid deposits in mice with the 6-kb upstream insert was more severe than in mice 
with the 0.6-kb insert. However, no TTR immunoreactivity or amyloid deposits were found in 
peripheral nerves of either mouse types. 
Additional TTR Tg mice transfected with the human wild type TTR gene and an L55P mutant 
TTR gene (leucine substituted for proline at the human TTR 55 residue) were developed by 
Sousa and Teng et al. (Sousa et al., 2001; Teng et al., 2001). Mice with the L55P TTR mutant did 
not reveal amyloid deposition at 2.5 years because they had only one copy of the inserted 
gene. In contrast, mice with wild type TTR gene, which had 100 copies inserted, revealed 
amyloid deposits consisting of TTR in the heart, gastrointestinal tract, and kidneys at 18 
months. Amyloid-affected male mice were more abundant than amyloid-affected female mice. 
Thus, the incidence and histopathological features mimicked human SSA. Furthermore, TTR 
immunoreactivity was observed in both females and males before the appearance of 
congophilic amyloid deposits formed, as the early stage of FAP (Sousa et al., 2002). 
However, amyloid deposits in Tg mice are less frequently observed than in human SSA or 
FAP cases. Indeed, amyloid formation is inhibited by the human/mouse hybrid hetero-
tetramer TTR in all Tg mice lines, which is extremely stable biochemically (Reixach et al., 
2008; Tagoe et al., 2007). Human TTR immunoreactivity of amyloid deposits increased in 
interstitial tissues of a crossbreed between L55P TTR Tg and TTR null-mice due to decreased 
formation of the hybrid hetero-tetramer TTR (Tagoe et al., 2007). 
An association between co-factors and TTR-amyloid formation in Tg mice is easy to confirm. 
Another line of crossbred mice (KO) was developed between L55P TTR Tg and heat shock 
factor protein 1 (HSF1), a TTR molecular chaperone protein in KO mice (Santos et al., 2010). 
These mice showed 2–3-fold more frequent amyloid deposits than in wild type TTR Tg mice 
and revealed TTR immunoreactivity not only in the cutaneous tissues and gastrointestinal 
system but also in the peripheral nerves at 3 months of age. The extra-neural tissue lesions 
developed further into congophilic amyloid deposits, whereas those in peripheral nerves 
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did not. TTR immunoreactivity in peripheral nerves is thought to be an early change prior to 
congophilic amyloid formation (Sousa et al., 2001). 
A retinol-biding site occurs at residue 84 in the TTR amino acid sequence. TTR Tg mice with 
I84S (isoleucine substituted for serine at human TTR residue 84) failed to show any amyloid 
deposits (Waits et al., 1995). 
According to the findings from these crossbred mice, strong overexpression of the mutant 
TTR gene is insufficient for TTR amyloid fibrogenesis. Amyloid formation increase in V30M 
TTR Tg mice were maintained under standard conditions but not under specific pathogen-
free conditions (Inoue et al., 2008; Noguchi et al., 2002), suggesting that microbiological 
conditions and consequent immunological events are closely associated with amyloid 
formation. Amyloid formation is required not only for misfolding of the precursor proteins 
but also other factors including microbiological exposure to the immune system 
(Muchowski, 2002; Noguchi et al., 2002). Moreover, possible associations with chaperone 
proteins, such as amyloid P component, apolipoprotein E, and HSF1 should also be 
considered (Nakamura et al., 2008; Santos et al., 2010; Wood et al., 2005). 
Other than Tg rodents, amyloid deposits consisting of mouse endogenous TTR have been 
found in senescence-accelerated mice, but this is supported by only one spontaneous report 
of TTR amyloidosis in rodents (Higuchi et al., 1991), although the strain in this report 
possessed a unique genetic background. Ueda et al. (2007) reported a TTR Tg rat transfected 
with V30M TTR that was TTR immunoreactive but did not have congophilic amyloid 
deposition in the gastrointestinal tract.  
2.2 Nonhuman primate models 
TTR amyloidosis has been reported in two male vervet monkeys (Table 1, cases 3 and 5) 
(Chambers et al., 2010, Nakamura et al., 2008), and we obtained one additional aged male case 
(Table 1, case 4) that revealed TTR amyloid deposits (data not shown). The remaining four 
monkeys (Table 1, cases 1, 2, 6, and 7) were examined histopathologically but did not contain 
amyloid deposits. Although all positive cases were males (similar to human SSA findings), 
understanding the epidemiological aspects of the disease is expected with additional cases. A 
characteristic symptom in case 5, mimicking human SSA, was an arrhythmia detected by 
electrocardiography (Fig. 1), whereas the SSA characteristics were confirmed by gross and 
histopathological findings in case 3. In both cases, the hearts revealed dilatation of both 
ventricles at necropsy, but the dilatation in case 3 was more severe than in case 5. In contrast, 
the histopathological density of amyloid deposits was more severe in case 5 than in case 3. The 
most severe amyloid deposits were observed in the heart of case 5. Myocardium and stroma 
were multifocally replaced by hyaline deposits as amyloid. The amyloid deposits were further 
found in the thyroid gland, tonsils, salivary glands, trachea, esophagus, thymus, lungs, 
gastrointestinal organs, kidneys, prostate gland, urinary bladder, lymph nodes, and skeletal 
muscle. In case 3, amyloid deposits were observed not only in the heart, gastrointestinal tract, 
liver, spleen, and kidneys, but also in the tenosynovium tissues, which were grossly 
hemorrhaged. These amyloid deposits are resistant to potassium permanganate, show apple 
green birefringence under a polarizing microscope (Fig. 2), and are TTR immunopositive (Fig. 
3). Although most amyloid deposits in vervet monkeys are consistent with TTR 
immunoreactivity, TTR immunopositivity without congophilic amyloids was observed only in 
the testes of case 5. These were thought to be non-fibrillar precursor amyloid deposits that 
occur prior to congophilic amyloid deposits (Sousa et al., 2001, Teng et al., 2001). 
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Cause of death 
*** TTR-amyloid
deposits
1 17 F E Uterine myoma -
2 25 M E Cardiac failure -
3 26 M Z Cardiac failure +
4 27 M E Thoracic tumor +
5 29 M E Cardiac failure +
6 >30 F E ND -
7 >30 F Z ND -
*: F; Female, M; Male
**: E; Experimental Animal Facility, Z; Zoo
***: ND; Not determined
+: Positive
-: Negative  
Table 1. Profiles of postmortem specimen of aged vervet monkey. 
 
 
Fig. 1. Arrhythmia detected by electrocardiography in case 5. 
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Fig. 2. Apple green birefringence was observed under a polarizing microscope in the heart 
of case 5; Congo red staining; bar, 25 µm. 
 
 
Fig. 3. Transthyretin (TTR) immunoreactivity in the heart of case 5; TTR immunostain; bar, 
50 µm. 
We observed seven vervet monkey cases (Table 1; average age, 26.3 ± 1.71 years; range, 
17–30 years). Three of the four males were positive for amyloid deposits, whereas all three 
females were negative. The incidence of TTR in aged male monkeys seems to be very high 
and reflects the features of human SSA (Rapezzi et al., 2010). In contrast, 42 cynomolgus 
monkeys (Macaca fascicularis; average age, 18.5 ± 1.33 years; range, 4–36 years) failed to 
show any TTR immunoreactivity or amyloid deposits in heart specimens (data not 
shown). 
Both vervet and cynomolgus monkeys belong to Cercopithecoidea, and they have a close 
evolutionary relationship. However, the onset of TTR amyloidosis differs, which may be 
due to differences in amino acid sequences. The TTR amino acid sequence in nonhuman 
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primates has been clarified in the chimpanzee (Pan troglodytes, AAV41026; Nadezhdin et 
al., 2001), orangutan (Pongo abelii, CAI29591), cynomolgus monkey (BAC20609), rhesus 
monkey (Macaca mulatta, XP_001099005), common marmoset (Callithrix jacchus, 
XP_002757195), and Bolivian squirrel monkey (Saimiri boliviensis, AAV74285) (Fig. 4). 
Homologies between human and nonhuman primate TTRs (including the signal peptide) 
are 97.3% with chimpanzee, 95.2% with orangutan, 93.9% with cynomolgus monkey, 
93.2% with rhesus monkey, and 78.9% with the common marmoset and Bolivian squirrel 
monkey. The lower homology with New world monkeys (marmoset and squirrel monkey) 
is due to a deletion of four to six residues and some TTR N-terminal substitutions. The 
homology of human and mouse TTRs is 81.0%. Although human FAP is induced by an 
amino acid substitution, major residues with substitution in FAP (residues at 30, 33, 45, 
53, 55, 60, 69, 77, 84, 88, 111, and 122) (Rapezzi et al., 2010) are conserved as human wild 
type in nonhuman primate species. The TTR amino acid sequence in vervet monkeys is 
expected to be clarified and is predicted to be very similar to cynomolgus and rhesus 
monkeys because they are very closely related species, belonging to Cercopithecoidea. 
However, substitution at the mutated residue position in FAP is predicted in vervet 
monkeys. 
 
-20 -19 -18 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Human M A S H R L L L L C L A G L V F V S E A G P T G T G E S K C P L M V K V L D A
Chimpanzee M A S H R L L L L C L A G L V F V S E A G P T G T G E S K C P L M V K V L D A
Orangutan M A S H R L L L L C L A G L V F V S E A G P T G A G E S K C P L M V K V L D A
Cynomolgus monkey M A S H R L L L L C L A G L V F V S E A G P T G V D E S K C P L M V K V L D A
Rhesus monkey M A S H R L L L L C L A G L V F V S E A G P T G V D E S K C P L M V K V L D A
Marmoset M A S H R L L L L C L A G L V F V S E A G P T  -  -  - G Y S C P L M V K V L D A
Borivian squirrel monkey M A S H H L L L L C L A G L V F V S E A G H T  -  -  - G Y S C P L M V K V L D A
Mouse M A S L R L F L L C L A G L V F V S E A G P A G A G E S K C P L M V K V L D A
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Human R G S P A I N V A V H V F R K A A D D T W E P F A S G K T S E S G E L H G L T T
Chimpanzee R G S P A I N V A V H V F K K A A D E T W E P F A S G K T S E S G E L H G L T T
Orangutan R G S P A V N V A V N V F K R A A D E T W E P F A S G K T S E S G E L H G L T T
Cynomolgus monkey R G S P A V N V A V N V F K K A A D E T W A P F A S G K T S E S G E L H G L T T
Rhesus monkey R G S P A V N V A V N V F K K A A D E T W A P F A S G K T S E S G E L H G L T T
Marmoset Q G R P A V N V A V S V F K K A A D E T W E P F A F G K T S E S G E L H G L T T
Borivian squirrel monkey Q G R P A I N V A V S V F K K A A D E T W E P F A L G K T S E S G E L H G L T T
Mouse R G S P A V D V A V K V F K K T S E G S W E P F A S G K T A E S G E L H G L T T
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
Human E E E F V E G I Y K V E I D T K S Y W K A L G I S P F H E H A E V V F T A N D S
Chimpanzee E E E F V E G I Y K V E I D T K S Y W K A L G I S P F H E H A E V V F T A N D S
Orangutan E E E F V E G I Y K V E I D T K S Y W K A L G I S P F H E H A E V V F A A N D S
Cynomolgus monkey E E E F V E G I Y K V E I D T K S Y W K S L G I S P F H E H A E V V F T A N D S
Rhesus monkey E E E F V E G I Y K V E I D T K S Y W K S L G I S P F H E H A E V V F T A N D S
Marmoset E E K F V K G V Y K V E I N S K S Y W H T L G I T S F H E H A D V V F S A N D S
Borivian squirrel monkey E E K F V K G I Y K V E I D S K S Y W H N L G I A S F H E H A D V V F A A N E S
Mouse D E K F V E G V Y R V E L D T K S Y W K T L G I S P F H E F A D V V F T A N D S
101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127
Human G P R R Y T I A A L L S P Y S Y S T T A V V T N P K E
Chimpanzee G P R R Y T I A A L L S P Y S Y S T T A V V T I P K E
Orangutan G P R R Y T I A A L L S P Y S Y S T T A V V T N P K E
Cynomolgus monkey G P R H Y T I A A L L S P Y S Y S T T A V V T N P K E
Rhesus monkey G P R H Y T I A A L L S P Y S Y S T T A V V T N P K E
Marmoset G P R H Y I V A A L L S P Y S Y S T T A V V S D P R K
Borivian squirrel monkey G P R H Y I V A A L L S P Y S Y S T T A V V S D P K N











Fig. 4. Amino acid sequences of TTR in nonhuman primate species, as compared with that in 
human and mice. 
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3. Discussion and conclusion 
At present, animal models for TTR amyloidosis are restricted to Tg rodents and vervet 
monkeys. The vervet monkey more obviously reflects the clinical symptoms and 
histopathological features of human SAA compared to those of TTR Tg mice (Nakamura et 
al., 2008), as some Tg mice lines do not reveal sufficient congophilic amyloid deposits. 
Because mice do not show spontaneous TTR amyloidosis but form extensive amyloid 
deposits following transfection with the human wild type or mutant TTR genes, the higher 
homology of TTR with humans may be important. Thus, the TTR amino acid sequence is 
key for primary amyloid formation. However, even if mutant TTR genes are strongly 
expressed in mice, amyloid formation has not been found in the peripheral nerves of any 
TTR Tg mice lines. Vervet monkeys also do not form TTR amyloid deposits in peripheral 
nerves, even if abundant TTR amyloid is deposited in extra-neural organs. Amyloid 
deposition of TTR in peripheral nerves is exclusively a human phenomenon, observed as 
terminal TTR amyloidosis lesions. Namely, other factors, such as molecular chaperones, 
immunological events, and time are required for development of TTR amyloidosis lesions 
prior to deposits in peripheral nerves. 
For example, differences between human and animals are well known in animal models of 
Alzheimer’s disease (AD). Senile plaques (SPs), consisting of amyloid protein (Aβ) and 
amyloid formation, are found in various mammalian species other than rodents (Selkoe et 
al., 1987), whereas neurofibrillary tangles (NFTs), consisting of phosphorylated tau, are 
found mostly in humans. In general, SPs appear first and NFTs appear consequently in the 
brain during the development of AD pathology. In mammalian species other than humans, 
the formation of NFTs is restricted to very old macaque monkeys (Oikawa et al., 2010). The 
Aβ amino acid sequence is completely homologous between humans and most mammalian 
species but not in rodents (Selkoe et al., 1987), and SPs can be found in various mammalian 
species. Furthermore, Tg mice transfected with mutant Aβ precursor protein (APP) show 
well developed SP formation but little or only slight formation of NFTs, whereas double Tg 
mice lines with APP and one of some other factors, such as presenilin-1, also form NFTs 
(Ashe et al., 2010). Thus, the formation of NFTs at the later stage of AD pathology is a 
phenomenon particular to humans, and not only Aβ amino acid sequence homology but 
also some other factors are required to develop NFTs in mammalian species. 
When animals develop the pathological changes of TTR and Aβ amyloidosis, the lesions 
seem to stop developing at the middle period before reaching the terminal period, as in 
humans. Unfortunately, the factors participating as thresholds for the onset of these diseases 
are unknown. Absolute time, amino acid sequence, the presence of molecular chaperones, 
and other factors may lead to these differences between humans and animals. Of these 
factors, life span is easy to understand. The longest lived cynomolgus monkey was 36 years 
(Oikawa et al., 2010), which is less than one-third of the longest lived human. More 
importantly, how a long term event that occurs in humans is shortened by model animals 
may be very difficult to ascertain. 
TTR Tg mice are useful for basic in vivo studies, whereas aged male vervet monkeys are 
useful for developing novel therapeutic chemicals and diagnostic materials in preclinical 
studies. Vervet monkeys have often been used to provide red blood cells for the measles 
hemagglutination inhibition test. However, the number of captive vervet monkeys is 
decreasing in Japan because of new diagnostic methods for measles (Fujino et al., 2007). 
Although there is a US primate center with a vervet monkey colony 
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funds are insufficient for maintaining such a huge facility in Japan. Shimozawa et al. (2010) 
developed embryonic stem cells from a vervet monkey, which may help reproduce them in 
the future. Now, captive vervet monkeys possess a novel raison d’etre under the field of 
biomedical science based on characteristics similar to human SSA. Here, we propose vervet 
monkeys as a novel biomedical science resource that will contribute to understanding TTR 
amyloidosis. 
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